Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma by Friedmann, Daniel et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2011, Article ID 289673, 6 pages
doi:10.1155/2011/289673
Clinical Study
Incidenceand Severity of LymphoedemafollowingLimb Salvage
of Extremity Soft Tissue Sarcoma
Daniel Friedmann,1 Jay S. Wunder,2,3 Peter Ferguson,2,3 Brian O’Sullivan,4 David Roberge,5
Charles Catton,4 Carolyn Freeman,5 NeilSaran,1 and Robert E. Turcotte1
1Division of Orthopedic Surgery, McGill University Health Centre, Montreal, QC, Canada H3G 1A4
2Musculoskeletal Oncology Unit Division of Orthopedic Surgery, Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5
3Department of Surgical Oncology, Princess Margaret Hospital, Toronto, ON, Canada M5G 2C4
4Department of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada M5S 3S2
5Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada H3G 1A4
Correspondence should be addressed to Robert E. Turcotte, robert.turcotte@muhc.mcgill.ca
Received 17 August 2011; Revised 28 September 2011; Accepted 28 September 2011
Academic Editor: Luca Sangiorgi
Copyright © 2011 Daniel Friedmann et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background and Purpose. Lymphoedema is a serious complication following limb salvage for extremity soft tissue sarcomas (STSs)
for which little is known. We aimed to evaluate its incidence, its, severity and its associated risk factors. Material and Method.
Patient and tumor characteristics, treatment modalities and complications and functional outcomes (MSTS 1987, TESS), and
lymphoedema severity (Stern) were all collected from prospective databases. Charts were retrospectively abstracted for BMI and
comorbidities.Results.Therewere289patients(158males).Meanagewas53(16–88).Followuprangedbetween12and60months
with an average of 35 and a median of 36 months. Mean BMI was 27.4 (15.8–52.1). 72% had lower extremity tumors and 38%
upper extremity. Mean tumor size was 8.1cm (1.0–35.6cm). 27% had no adjuvant radiation, 62% had 50Gy, and 11% received
66Gy. The incidence of lymphoedema was 28.8% (206 none, 58 mild, 22 moderate, 3 severe, and 0 very severe). Mean MSTS score
was 32 (11–35) and TESS was 89.4 (32.4–100). Radiation dose was signiﬁcantly correlated with tumor size > 5cm(P = 0.0001)
and TESS score (P = 0.001), but not MSTS score (P = 0.090). Only tumor size > 5cm and depth were found to be independent
predictors of signiﬁcant lymphoedema. Conclusion. Nine percent of STS patients in our cohort developed signiﬁcant (grade ≥ 2)
lymphoedema. Tumor size > 5cm and deep tumors were associated with an increased occurrence of lymphoedema but not
radiation dosage.
1.Introduction
Soft tissue sarcomas (STSs) comprise a group of rare malig-
nant tumors occurring most commonly in the extremities
[1, 2]. Preferred treatment for patients with STS is limb pre-
servation surgery usually in combination with adjuvant pre-
operative or postoperative radiation therapy [1, 3–7]. This
treatment carries a signiﬁcant risk of functional disability
and reduced quality of life [6, 8] ,a n du pt o5 0 %o fp a t i e n t s
live with signiﬁcant long-term disability [9].
Studiesthathavecomparedpreoperativetopostoperative
external-beam radiotherapy (EBRT) as part of limb sparing
surgery for patients with extremity STS have shown that,
while preoperative EBRT allows the use of lower doses and
smaller treatment ﬁelds, such an approach is associated with
increased risk of acute wound healing complications [3, 6,
10]. Postoperative EBRT typically requires the use of higher
radiation doses and larger target volumes and is associated
with increased late radiation-related morbidity [3, 11]. One
important complication which has been given very limited
attention thus far is secondary lymphoedema.
Lymphoedema is swelling that generally occurs in the
limbs, or less commonly in visceral and axial structures, due
to an accumulation of protein-rich lymph ﬂuid in the inter-
stitial tissues [12, 13]. In patients with STS, lymphatic injury
may result from surgical disruption of lymph nodes, lym-
phatic or major blood vessels. Alternatively, the lymphatic
system may be damaged by radiotherapy leading to ﬁbrosis2 Sarcoma
and compromised lymph transport [12]. Patients presenting
withlymphoedemasecondarytotreatmentforSTSareprone
to developing recurrent infections and skin changes such as
hyperkeratosis and papillomatosis [14]. Beyond the physical
symptoms and signs, lymphoedema may also be associated
with signiﬁcant psychological and functional morbidities
such as poor body image leading to anxiety and depression
[15].
Lymphoedema in the upper extremities has been studied
extensively in the breast cancer population. The frequency of
occurrence is extremely variable ranging from 3% to 83%,
although generally accepted to be approximately 30% [16–
19]. Several predisposing factors have been identiﬁed, most
importantly axillary surgery (lymph node dissection) and
axillary radiotherapy [15, 17, 19, 20]. Other factors which
may also inﬂuence the risk of lymphoedema in the breast
cancer population include the stage at diagnosis, systemic
therapies (chemotherapy or hormonal therapy), age, body
mass index, hypertension, history of infection, and pretreat-
menteducationregardinglymphoedemaandpreventiveself-
care activities [2, 15, 17, 21, 22].
Fewstudieshaveaddressedthequestionoflymphoedema
in patients with STS, which occurs most commonly in the
lower extremities [2, 4, 8]. Previous soft tissue sarcoma ser-
ies reported an incidence of lymphoedema of 30% while
others recorded signiﬁcant lymphoedema (grade ≥2) in 19%
[4, 8, 18, 23]. High biologically eﬀective dose (BED), radi-
a t i o nﬁ e l dl e n g t h>35cm and lower extremity location were
identiﬁedaspositiveriskfactorsforthedevelopmentofchro-
nic oedema.
The objective of this study was to identify the incidence
and the severity of lymphoedema, and to evaluate the poten-
tial risk factors in patients with extremity soft tissue sarcoma
whohaveundergonelimbpreservationsurgerywithorwith-
out adjuvant external beam radiotherapy.
2. Methods
Our prospective tumor database served to identify patients
who had undergone surgical management of extremity STS
attheMontrealGeneralHospital,Montreal,Quebec,andthe
Mount Sinai Hospital, Toronto, Ontario, between 2000 and
2007. All patients selected for inclusion in this study had
prospective collection of lymphoedema severity rating at an
interval of at least 1 year following treatment. Lymphoedema
severity was evaluated using Stern’s Rating Scale for Edema.
Stern’s scale is a subjective, physician-rated measure with
scores ranging from 0 to 4 (Table 1)[ 25]. Functional out-
comes were assessed using the Musculoskeletal Tumor Soci-
ety Rating scale (MSTS) and the Toronto Extremity Salvage
Score(TESS).TheMSTSisaclinician-ratedscalewhicheval-
uates pain, joint range of motion, strength, joint stability,
joint deformity, overall function, and general acceptance of
the treatment; the score ranges from 0 to 35 [24]. The TESS
is a patient-rated measure developed speciﬁcally for patients
undergoing limb salvage surgery for bone and soft tissue sar-
c o m a sw h i c he v a l u a t e sd i ﬃculty performing daily activities
[26]. All three outcomes were collected simultaneously at
a mean interval of 35 months from treatment (range 12–60).
Table 1: Stern’s Rating Scale for Edema [24].
Score Rating
0N o n e
1 Mild (but deﬁnite swelling)
2M o d e r a t e
3 Severe (considerable swelling)
4 Very severe (skin shiny and tight ± skin cracking)
Patients’ demographics, tumor characteristics, and treat-
ment-related variables were prospectively collected. Charts
were also retrospectively abstracted for body mass index
(BMI) and to identify medical comorbidities including the
occurrence of thrombophlebitis.
The association between size of the tumor and the like-
lihood of having signiﬁcant lymphoedema (grade 2 or 3)
was modeled using logistic regression. Tumor size was cate-
gorized as small or large with large representing tumors 5cm
or greater, and the small category was used as the reference
for the analysis. The following variables were included as in-
dependent variables to obtain adjusted eﬀects:agewas a con-
tinuousvariable,andsex,BMI,upperversuslowerextremity,
whether or not a lymph node dissection was performed,
radiation, and smoking were categorical variables with male
sex, BMI <30kg/m2, upper extremity, no node dissection,
no radiation, and nonsmoker coded to serve as reference
categories. Initially, depth of the tumor was also included as
a variable; however, seeing as there were no cases of lym-
phoedema in the superﬁcial group, this had to be removed
from the analysis. Regression coeﬃcients were exponentiat-
ed to determine the odds ratio (OR) of signiﬁcant lymphoe-
dema compared to nonsigniﬁcant lymphoedema for a large
tumor as compared to a small tumor. The log-likelihood
ratiotestwasusedtoassessthesigniﬁcanceoftheassociation
ﬁtted by the model, and individual regression estimates are
tested by Wald statistics for signiﬁcance by assessing the null
hypothesis that the regression estimates are equal to zero.
A P-value of 0.05 was used as the cut-oﬀ for signiﬁcance.
All statistical analyses were performed using SPSS 19 (IBM,
Armonk, NY).
3. Results
288 patients met the inclusion criteria of whom 55% were
male. The mean age was 53 years (range 16–88). Mean body
mass index (BMI) was 27.43 (range 15.8–52.1). 73% of pa-
tients presented with lower extremity tumors. Speciﬁc tumor
locations, in order of frequency, were as follows: quadriceps
(N = 95), adductor (N = 43), shoulder (N = 38), elbow/
forearm (N = 36), hamstring (N = 26), knee (N = 17),
ankle/foot (N = 15), buttock (N = 12), and hand (N = 6).
Average tumor size was 7.4cm (range 1.0–35.6). Tumor his-
tology, in order of frequency, was as follows: MFH (N = 74),
liposarcoma (N = 64), leiomyosarcoma (N = 30), synovial
(N = 28), ﬁbrosarcoma (N = 2 5 ) ,D F S P( N = 12), MPNST
(N = 10), osteosarcoma (N = 10), rhabdomyosarcoma
(N = 2), and other (N = 23). Patient demographics and
tumor and clinical characteristics are given in Table 2.Sarcoma 3
Table 2: Patient demographics and tumor and clinical characteris-
tics in relation to lymphoedema severity.
Variable (N) Lymphoedema <2 Lymphoedema ≥2
Age at surgery (288)
Mean 52 58
Range 16–86 19–88
Gender (288)
Male 144 14
Female 119 11
Presenting status (288)
Primary 249 24
Local recurrence 12 1
Unplanned 2 0
Extremity (288)
Upper 59 22
Lower 204 3
Tumor size (288) [cm]
Mean 7.1 11.4
Range 1.0–35.6 4.5–20.5
Tumor depth (288)
Superﬁcial 78 0
Deep 185 25
AJCC Stage (272)
IA 42 0
IB 18 0
IIA 63 8
IIB 52 2
IIC 12 1
III 62 12
Radiation therapy was administered preoperatively (50Gy)
for 184 patients, postoperatively (66Gy) for 21 patients, and
both pre- and postoperatively (50 + 16Gy) for 7 patients. 76
patients received no radiation therapy. Table 3 shows treat-
ment modalities in patients with none or minimal lympho-
edema and in those with more severe limb swelling.
Posttreatmentlymphoedema wasidentiﬁed in 29%(N =
83)ofpatients.Mildlymphoedema(grade1)wasobservedin
58 patients, moderate (grade 2) in 22, and severe (grade 3)
in 3. Patients with moderate and severe lymphoedema were
grouped together and compared with a second group con-
sisting of patients with either mild or no lymphoedema. The
incidence of signiﬁcant posttreatment lymphoedema (i.e.,
grade ≥2) was 9%. Seven patients developed post-operative
thrombophlebitis, and all of them had subsequent lympho-
edema rated as none (6) or mild (1). We found 16 patients
whounderwent lymph node dissection (5.5%).Among these
2 received 66Gy, 10 received 50Gy, and 4 received no rad-
iation. Out of those 16 patients, 3 patients had signiﬁcant
lymphoedema, 6 showed mild lymphoedema, and 7 had
none; thus 13 of the 16 did not demonstrate signiﬁcant
lymphoedema. The radiation dose administered was signif-
icantly correlated with tumor size >5cm(P = 0.0001) and
tumor depth (P<0.001), but not tumor location (i.e., upper
Table 3:Lymphoedema severity versuswound closure, tissueresec-
ted, and comorbidities.
Variable (N) Lymphoedema
<2
Lymphoedema
≥2
Surgical closure (288)
Primary 194 20
Free ﬂap + STSG 14 3
STSG only 46 0
Other 9 2
Tissues resected
Skin/subcutaneous 176 21
Muscle 122 21
Bone 20 2
Nerve 27 3
Vessels 18 2
Comorbidities
Myocardial infarction 37 2
Coronary artery disease 22 4
Hypertension 86 7
Deep vein thrombosis 7 0
Renal failure 6 0
Diabetes type II 17 3
Ulcer 4 2
versus lower extremity, P = 0.334). Higher radiation dosage
was also signiﬁcantly correlated with lower TESS score (P =
0.001), but not MSTS score (P = 0.090).
Univariateanalysisidentiﬁedsigniﬁcantcorrelationsbet-
ween the severity of lymphoedema and radiation dose (50
versus 66Gy; P = 0.010), tumor size (>5cm;P = 0.011),
and deep location (P = 0.001). We found no signiﬁcant cor-
relation between the severity of lymphoedema and tumor
location (upper versus lower extremity) or lymph node dis-
section.Wealsofoundnosigniﬁcantassociationbetweenthe
incidence of lymphoedema and the body mass index (BMI),
hypertension, or smoking.
In the group of patients with deep tumors, the incidence
of signiﬁcant lymphoedema was 12%. There were no cases of
lymphoedema in the superﬁcial tumor group (χ2 = 10.168,
P = 0.001) irrespective of the amount of radiation received.
The unadjusted OR of signiﬁcant lymphoedema (grade 2 or
3) in large (5cm or greater) as compared to small (less than
5cm) tumors was 19.7 (P = 0.004; 95% CI: 2.6 to 148.8) and
the adjusted OR was 12.4 (P = 0.02; 95% CI: 1.5 to 100.9)
(Table 4). The computed log-likelihood ratio test was 98.99
with 8 degrees of freedom and P = 0.006 suggesting that at
least one of the regression coeﬃcients is diﬀerent from zero.
These results show that lymphoedema was strongly associ-
ated with the size of the tumor.
4. Discussion
Therehavebeenveryfewreportsaddressingtheincidenceand
severity of lymphoedema following modern management of4 Sarcoma
Table 4: Logistic regression coeﬃcients with Corresponding P values, odds ratios, and 95% conﬁdence intervals of the odds ratios.
Variable Regression
coeﬃcient Std. error Wald (df = 0) P Odds ratio
95% Conﬁdence Interval
for odds ratio
Lower bound Upper bound
Constant −7.06 1.77 15.964 0.000 0.001
Age (years) .021 0.018 1.460 0.227 1.022 0.987 1.058
Sex (male) −0.330 0.550 0.360 0.548 0.719 0.244 2.113
Extremity (Lower) 1.463 0.870 2.829 0.093 4.320 0.785 23.765
BMI (≥30) −.671 0.738 0.826 0.363 0.511 0.120 2.173
Tumor size (large) 2.515 1.071 5.517 0.019 12.372 1.516 100.932
Lymph node
Dissection 1.705 1.017 2.811 0.094 5.504 0.750 40.407
Radiation 0.219 0.712 0.095 0.758 1.245 0.309 5.019
Smoking 0.505 0.556 0.826 0.364 1.657 0.558 4.923
B M I :b o d ym a s si n d e x .A g ew a sac o n t i n u o u sv a r i a b l e .S e x ,e x t r e m i t y ,B M I ,t umor size, lymph node dissection, radiation, and smoking are categorical values
with reference categories as follows: male sex, upper extremity, BMI <30kg/m2,t u m o rs i z e<5cm, no node dissection, no radiotherapy, and nonsmoker.
soft tissue sarcoma of the extremities. Reasons for the rare
occurrence of sarcoma, the need for large number of pa-
tients,andsigniﬁcantdisparitiesamongtumor,location,and
management in contrast to breast or gynaecologic cancers.
This series consists of a large number of patients treated in a
multidisciplinary setting with prospective data collection in-
cluding lymphoedema severity assessment and function out-
comes. We recorded an overall incidence of 29% of lympho-
edema in sarcoma of the extremities which is identical to a
previous report [8].
We elected to use Stern’s Rating Scale of lymphoedema
severity as it is relatively simple and has been used as part of
ourcombinedprospectivedatacollectionforyears.However,
eveninexperiencedhands,thisclassiﬁcationremainssubjec-
tiveandsomewhatimpreciseandnointra-andinterobserver
reliability tests have been performed to demonstrate its val-
idity.Additionally,ithasbeensuggestedthatqualitativemea-
surements of lymphoedema may minimize its true incidence
[27]. Despite the need for quantitative tools to assess lym-
phoedema severity [28], recent proposals addressing this
topic have only led to minor variations and Stern’s Rating
ScaleisverysimilartothoseendorsedbytheNationalCancer
Institute (NCI) and the Radiation Therapy Oncology Group
(RTOG) [12, 29].
There are important limitations in the current study. The
number of patients enrolled in this study remains relatively
small to provide for suﬃcient power in subset analyses. All
patients treated for extremity soft tissue sarcoma were not
systematically included. Lymphoedema grading was manda-
tory for inclusion in the study, and an unknown number
of cases may have been excluded if recording was omitted.
Patients who died or were lost to followup within the ﬁrst
year following treatment were also excluded. Risk factors
suchassmokinghabits,bodymassindex,andmedicalcomo-
rbidities were also not prospectively and systematically col-
lected for all patients leading to softer conclusions about
their role in the occurrence of lymphoedema. Timing for the
recording of lymphoedema may also be important as it may
appear or get worse over many years [27, 28]. With median
and average follow-up periods of 3 years from the index pro-
cedure it was likely that we captured most of the severe cases.
We could not identify whether there were patients who
underwent lymphoedema treatments prior to or at the time
of recording lymphoedema severity. Although thrombophle-
bitis, an important cause of chronic extremity swelling, was
not systematically recorded, we did not identify any signiﬁ-
cant swelling in the 7 patients who suﬀered a recognized
thrombotic event. Moreover our study was likely under-
powered to detect the expected increased incidence of chro-
nic swelling in lower limb tumor or following lymph nodes
dissection.Perhapsthemostimportantlimitationtothecon-
clusions of this work was the discrepancy and the relative
small number of patients including those that received 66Gy
of radiotherapy demonstrating a clear bias toward neoadju-
vant radiotherapy. The timing of radiation therapy in the
treatment of soft tissue sarcoma remains controversial. In a
prospective randomized study, it was shown that neoadju-
vant radiotherapy led to a postsurgical wound complication
rate of 34% in the preoperative group compared to 17%
whenradiationwasadministeredpost-operatively[18].Fun-
ctional status, as per the Toronto Extremity Salvage Score,
was found to be identical in both groups but, at a minimum
2-year followup, patients treated with higher dose postoper-
ative radiotherapy tended to have signiﬁcant ﬁbrosis, joint
stiﬀness, and edema, all of which correlated with worse fun-
ctional outcomes [4]. Similar ﬁndings were previously re-
ported [8]. Although univariate analysis identiﬁed a signif-
icant relationship between the occurrence of signiﬁcant lym-
phoedema and a total dose of 66Gy, radiotherapy was not
foundtobeassociatedwithlymphoedemausingmultivariate
analysis. Despite this, one must be careful in concluding no
associationasthenumberofpatientsinthisstudyarelimited
for such a conclusion. The possible beneﬁt of preoperative
radiation in minimizing some of the late treatment eﬀects
such as lymphoedema remains to be demonstrated. These
potential beneﬁts need to be balanced against the risk of
acute wound healing complications on an individual basis
withinthemultidisciplinarytreatmentsetting.TheimpactofSarcoma 5
wound complication of the incidence of lymphoedema also
remains unknown. We did not record and compare the rad-
iotherapy target volume. However, in our centers with well-
establishedmultidisciplinaryteams,itislogicaltoexpectthat
the radiotherapy target volume would correlate with tumor
volume. Thus, as for large tumors, a larger volume of tissue
irradiated would likely lead to increased incidence of late
treatment-related morbidity, including lymphoedema. addi-
tion, intensity modulated radiotherapy (IMRT) has become
routineinrecentyearsbecauseofimproveddosimetry,speci-
ﬁcally improved sparing of bone and joints as well as of skin
and other noninvolved tissues from high dose exposure. All
of these factors may be expected to lead to reduced late treat-
ment-relatedmorbidityinfuturepatients[30,31].Thelimit-
ed number of patients and heterogeneity of radiation modal-
ities meant that we could not perform useful comparisons.
The value of a postoperative boost of radiotherapy fol-
lowing standard 50Gy preoperative radiotherapy has been
putintoquestionrecentlyandmaybeunnecessarytoprevent
local recurrence [32]. Others have suggested that lower than
traditional postoperative radiotherapy doses reduce the oc-
currence of chronic sequelae without compromising local
control [33]. Although a lower dose of radiotherapy may be
safe we cannot recommend it for the prevention of lympho-
edema.
It remains unclear how function and quality of life relate
totheincidenceandseverityoflymphoedema.Inthecurrent
study, TESS scores were signiﬁcantly lower in patients who
received a higher dose of radiation therapy (P = 0.0001), but
MSTS scores did not correlate with radiation dosage. Func-
tional results from previous Canadian randomized clinical
trial found that both TESS and MSTS scores correlated with
skin ﬁbrosis, joint stiﬀness, and lymphoedema, and these
were dependant on the radiotherapy regimens [4]. Although
lymphoedema most likely impacts physical function, our
ﬁndings do not suggest that worse functional outcome is
mainly the result of lymphoedema.
The eﬀect of treatment on chronic lymphoedema also re-
mains unclear. Some have reported an overall improvement
in health-related quality of life (HRQOL) using the Notting-
ham Health Proﬁle Part-1 (NHP-1) as the main outcome
measure [34]. The treatment resulted in signiﬁcant changes
in the physical domains (e.g., mobility) but no signiﬁcant
changewasnotedintheemotionalorpsychologicaldomains.
Lymphedema can be a troublesome and important com-
plication of limb salvage treatment for STS. The overall inci-
dence of lymphedema in our study was 29% with signiﬁcant
(grade 2 or more) lymphedema occurring in 9% of patients.
Risk factors for lymphedema included depth of tumor and
tumors >5cm in size. Interestingly, radiotherapy was not
found to be signiﬁcantly associated with lymphedema. It has
been reported that cancer patients are not always informed
about lymphoedema symptoms or management and that the
usesofpreventionstrategiescouldbeimproved[17].Theoc-
currence of lymphoedema might be minimized through in-
creased awareness, education, and therapy. Prospective trials
are needed to determine the potential eﬀect of pretreatment
educationandprophylacticinterventions ontheincidenceof
lymphoedema in the STS population.
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